Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences

Lotrich, Francis E.; Bies, Robert R.; Muldoon, Matthew F.; Manuck, Stephen B.; Smith, Gwenn S.; Pollock, Bruce G.

doi:10.1007/s00213-004-2006-4

Cited by 26 publications

(32 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lotrich et al (2005) (Figure 3) reported a mean plasma citalopram concentration of circa 10 ng/mL between 45 and 150 mins after an infusion of 10 mg citalopram in healthy control subjects. Meyer et al (2004) (Figure 1) measured a striatal SERT occupancy of about 50% for a plasma citalopram concentration of 10 ng/mL in subjects who had received daily oral doses of citalopram for 4 weeks.…”

Section: Discussionmentioning

confidence: 99%

“…The dose and timing of the injection were based on previous studies showing robust and sustained effects of this dose of citalopram on anterior pituitary hormones-a putative marker of serotonergic system integrity (Attenburrow et al, 2001;Bhagwagar et al, 2002). As published by Lotrich et al (2005) (Figure 3), this schedule leads in healthy control subjects to a fairly stable citalopram plasma concentration of about 10 ng/mL between 45 and 150 mins after the start of the infusion with little between-subject variability.…”

Section: Subjects and Medicationmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Citalopram Infusion on the Serotonin Transporter Binding of [¹¹C]DASB in Healthy Controls

Hinz

Selvaraj

Murthy

et al. 2008

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

The positron emission tomography (PET) ligand [ 11 C]DASB is currently the most widely used imaging agent for quantitative studies of the serotonin transporter (SERT) in human brain. The aim of this work was to assess the effects of an intravenous infusion of 10 mg citalopram, a selective serotonin reuptake inhibitor (SSRI), before the PET scan on the kinetics of [ 11 C]DASB in arterial plasma and in selected brain regions. Four healthy male volunteers underwent two PET scans with a mean of 523 MBq injected activity after either placebo or citalopram infusion in a randomised design. The citalopram infusion led to a substantial increase of the area under the curve of the metabolitecorrected arterial plasma input function. Total volumes of distribution V T were estimated applying the Logan plot to regional time-activity curves or by generating parametric maps with spectral analysis. A mean reduction of the cerebellar V T of 19% with Logan analysis and of 24% with spectral analysis was observed after citalopram infusion, which confirms previous findings of displaceable SERT ligand binding in cerebellar grey matter. The SERT occupancy for six target regions with moderate to high binding was 60% derived from BP ND and 69% derived from BP P .

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Subjects and Medicationmentioning

confidence: 99%

Effects of Citalopram Infusion on the Serotonin Transporter Binding of [¹¹C]DASB in Healthy Controls

Hinz

Selvaraj

Murthy

et al. 2008

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

show abstract

“…Stimulation of hypothalamic 5-HT receptors promotes the pituitary release of prolactin, and citalopram increases serotonergic neurotransmission by highly selective inhibition of 5-HT reuptake. 14 The increase in circulating prolactin concentration induced by citalopram is dose-dependent 15 and provides an index of net serotonergic responsivity in the hypothalamic-pituitary axis. 3 Individual differences in prolactin response to serotonergic challenge are reasonably reproducible over 6 months (rϭ0.59 when menstrual cycling is controlled 16 ) and correlate across methods of assessment.…”

Section: Citalopram Challenge Testmentioning

confidence: 99%

“…Methods for determining serum prolactin and plasma citalopram concentrations have been described previously. 15 Prolactin concentrations from the two baseline prolactin samples were averaged.…”

Section: Citalopram Challenge Testmentioning

confidence: 99%

Lower Central Serotonergic Responsivity Is Associated With Preclinical Carotid Artery Atherosclerosis

Muldoon

Mackey

Sutton-Tyrrell

et al. 2007

Stroke

Self Cite

View full text Add to dashboard Cite

Background and Purpose-Central nervous system serotonergic neurotransmission appears to play a role in mood disorders, eating habits, and sleep, and also modulates blood pressure and metabolism. This investigation tested a hypothesized association between central serotonergic functioning and preclinical atherosclerosis. Methods-Subjects were 244 adults 30 to 55 years of age and free of clinically evident vascular disease (52% men, 84% white). Central serotonergic responsivity was measured as the rise in serum prolactin concentration (area under the curve) over 2.5 hours, adjusted for baseline prolactin, after citalopram administered intravenously at 0.33 mg/kg lean body weight. Carotid artery morphology served as a marker of preclinical atherosclerosis, and carotid artery intima-media thickness and plaque occurrence were determined by B-mode ultrasonography. Results-In linear regression models including age, gender, race, and citalopram concentration, a 1 SD lower prolactin response was associated with greater maximum intima-media thickness (ϩ0.016 mm; Pϭ0.006) and with greater mean intima-media thickness (ϩ0.009 mm; Pϭ0.03). The odds ratio for carotid artery plaque corresponding to a 1 SD decrease in prolactin response, adjusted for age, race, sex, and citalopram concentration, was 1.47 (95% CI, 0.98 to 2.19; Pϭ0.06). The metabolic syndrome mediated (PϽ0.01), but did not fully account for, the association between lower prolactin response and greater maximum intima-media thickness. Conclusions-In this young and relatively healthy sample, blunted prolactin response to citalopram was associated with carotid artery thickening, suggesting that individual differences in central serotonergic responsivity are inversely related to preclinical vascular disease.

show abstract

“…Healthy volunteers scoring high on depression related traits, for example, could be shown to resemble depressed patients in their responses to serotonergic stimulation by citalopram (e.g. Lotrich et al, 2005), or by clomipramine (Ruegg et al, 1997;Gerra et al, 2000). Similarly, increased cortisol responses to the noradrenaline reuptale inhibitor reboxetine in depressive healthy persons mirrored the effect of a noradrenergic challenge observed in depressed patients (Hennig et al, 2000), and a challenge by the dopamine D2 receptor agonist bromocriptine in healthy persons confirmed decreased dopaminergic activity observed in patients (Netter, 2006).…”

Section: Introductionmentioning

confidence: 77%

Discriminating Depression, Physical and Social Anhedonia by Neurotransmitter Related Challenge Tests

Netter¹,

Hennig²

2016

PSYCH

View full text Add to dashboard Cite

The aim of this study was to investigate, if anhedonia, a salient component of depression, shows similar response patterns to neurotransmitter challenge tests as depression, and if the two questionnaire based components Physical (PA) and Social (SA) Anhedonia can be discriminated by differences in drug related size and time of cortisol responses elicited by the specific serotonin (5-HT) and noradrenaline (NA) reuptake inhibitors citalopram and reboxetine and prolactin responses to the dopamine (DA) agonist bromocriptine orally applied to 36 male volunteers in a double blind balanced cross-over design. Analyses of variance applied to placebo corrected hormone responses revealed that low and late DA responses were characteristics of global Depression and of Physical Anhedonia, and that low DA responses were associated with high NA responses in PA, and with low 5-HT responses in SA. These patterns were explained by differences in transmitter production and receptor sensitivities and proved to be suitable to discriminate PA from SA and from global depression by analysing neurochemical response patterns rather than single means of variables.

show abstract

Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences

Cited by 26 publications

References 61 publications

Effects of Citalopram Infusion on the Serotonin Transporter Binding of [¹¹C]DASB in Healthy Controls

Effects of Citalopram Infusion on the Serotonin Transporter Binding of [¹¹C]DASB in Healthy Controls

Lower Central Serotonergic Responsivity Is Associated With Preclinical Carotid Artery Atherosclerosis

Discriminating Depression, Physical and Social Anhedonia by Neurotransmitter Related Challenge Tests

Contact Info

Product

Resources

About

Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences

Cited by 26 publications

References 61 publications

Effects of Citalopram Infusion on the Serotonin Transporter Binding of [11C]DASB in Healthy Controls

Effects of Citalopram Infusion on the Serotonin Transporter Binding of [11C]DASB in Healthy Controls

Lower Central Serotonergic Responsivity Is Associated With Preclinical Carotid Artery Atherosclerosis

Discriminating Depression, Physical and Social Anhedonia by Neurotransmitter Related Challenge Tests

Contact Info

Product

Resources

About

Effects of Citalopram Infusion on the Serotonin Transporter Binding of [¹¹C]DASB in Healthy Controls

Effects of Citalopram Infusion on the Serotonin Transporter Binding of [¹¹C]DASB in Healthy Controls